Introduction
============

Hepatocellular carcinoma (HCC) is a major health problem worldwide.[@b1-ott-12-2193],[@b2-ott-12-2193] It affects more than 500,000 people worldwide every year,[@b3-ott-12-2193] with a 5-year survival rate of 30%.[@b4-ott-12-2193] The poor prognosis is mainly attributed to a high rate of recurrence and metastasis.[@b5-ott-12-2193]

Epithelial--mesenchymal transition (EMT) plays an important role in cancer metastasis.[@b6-ott-12-2193],[@b7-ott-12-2193] EMT regulators such as VEGF-R are potential therapeutic targets;[@b7-ott-12-2193],[@b8-ott-12-2193] therefore, the identification of biomarkers related to EMT is important.

Long noncoding RNAs (lncRNAs) comprise more than 200 nucleotides that do not code for proteins and are widely expressed in various organs.[@b5-ott-12-2193],[@b9-ott-12-2193] They are involved in diverse biological/pathological processes such as epigenetic transcription/post-transcriptional regulation,[@b10-ott-12-2193]--[@b12-ott-12-2193] proliferation, and metastasis of cancer cells.[@b13-ott-12-2193],[@b14-ott-12-2193] Recently, lncRNAs have been verified to play a critical role in EMT.[@b15-ott-12-2193] LINC01296 is located at 14q11.2 and is upregulated to promote the cellular proliferation and invasion of cancers of stomach,[@b16-ott-12-2193] colon,[@b17-ott-12-2193] bile duct,[@b18-ott-12-2193] and prostate.[@b19-ott-12-2193] Yang et al demonstrated a higher than normal level of LINC01296 in primary HCC;[@b20-ott-12-2193] however, the biological implications of this remain unclear.

miRNAs and lncRNAs can interact with each other[@b21-ott-12-2193],[@b22-ott-12-2193] and affect cellular behavior;[@b22-ott-12-2193] recently, this has become an interesting field of research. miRNA-triggered lncRNA decay is the primary form of interaction between miRNAs and lncRNAs;[@b23-ott-12-2193] an example of this is the reduction in MALAT1 abundance by miR-9 directly binding to two sites in the sequence.[@b24-ott-12-2193] Meanwhile, lncRNAs can act as a sponge to reduce the regulatory effect of miRNAs.[@b25-ott-12-2193],[@b26-ott-12-2193] miR-122 has been extensively studied for its association with HCC[@b27-ott-12-2193] as it triggers EMT and suppresses cellular motility and invasion.[@b28-ott-12-2193] However, the interaction between LINC01296 and miR-122 in HCC is not yet thoroughly understood.

The aim of this study was to investigate the role of LINC01296 in the progression and metastasis of HCC and to further explore the negative regulation of the biological effect of LINC01296 by miR-122-5P.

Materials and methods
=====================

Clinical samples and cell lines
-------------------------------

Fifty pairs of HCC tissues and pericancerous tissues (PTs) were collected from 37 male and 13 female patients, who received treatment in The First Affiliated Hospital of Chongqing Medical University (Chongqing, China). The study used human tissues and it was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board. Signed informed consent was obtained from all the patients.

Human HCC cell lines (SMMC-7721, Hep3B, HepG2, and Huh7) and a normal hepatocyte cell line (HL-7702) were obtained from the China Center for Type Culture Collection (Wuhan, China). Cells were cultured in DMEM (HyClone, Logan, UT, USA) enriched with 10% FBS (Hyclone) and incubated in 5% CO~2~ at 37°C.

Microarray data
---------------

Differentially expressed lncRNAs with high abundance were screened from a microarray database supplied by Yang et al.[@b20-ott-12-2193] In the database, 323 upregulated and 525 downregu-lated RNAs were summarized as recurrently dysregulated lncRNAs in primary HCC samples from 20 HCC patients sequenced by total RNA-seq.

Bioinformatics database
-----------------------

Differentially expressed lncRNAs were compared between HCC and normal liver tissues using data from Gene Expression Profiling Interactive Analysis (GEPIA, <http://gepia.cancer-pku.cn/>). Furthermore, RNA-seq analysis was used to identify the expression of LINC01296 in HCC cohorts from The Cancer Genome Atlas (TCGA, <https://tcga-data.nci.Nih>. gov/tcga/). In total, 424 samples (50 normal liver tissues and 374 HCC tissues) were available for analysis of LINC01296 expression. In addition, LINC01296 expression levels and 10-year survival time data were collected from 370 HCC patients in the TCGA database to perform a survival analysis.

Reverse transcription quantitative PCR (RT-qPCR)
------------------------------------------------

mRNAs and miRNAs were extracted from cells or tissues using the Hipure Universal mRNA/miRNA kit (Magen, Guangzhou, China). RT-qPCR was performed using the all-in-one mRNA qPCR or miRNA qPCR Primer (Gene-Copoeia, Inc., Rockville, MD, USA). The protocol was as follows: 95°C for 10 minutes, 40 cycles at 95°C for 10 seconds, 60°C for 20 seconds, and 72°C for 15 seconds. The 2^--⊗⊗Cq^ method[@b29-ott-12-2193] was used to calculate the relative gene expression normalized by GAPDH or U6. The primers used were: 5′-CAAAGAGGGAGTAGTTGAGCAAGGTATG-3′ and 5′-CTGTGGCGACGGTGGAGGGATGT GAGTG-3′ for LINC01296; 5′-TGGCAGAGTTGCACAG AAGA-3′ and 5′-ACCACTCACACTTTCATCGCT-3′ for ZFPM2-AS1; 5′-TGAAGTCATCACGAACCG CA-3′ and 5′-GGAGCCCCAAGTTAATGCGA-3′ for ELF3-AS1; 5′-AATTTGCCACCACCCTGTGA-3′ and 5′-ATGCCGTTTTAGGGGGACAG-3′ for LINC00978; 5′-CCAGGGCTGCTTTTAACTCT-3′ and 5′-GGACTC CACGACGTACTCA-3′ for GAPDH; 5′-GGGGTGGAGT GTGACAATG-3′ and 5′-CAGTGCGTGTCGTGGAGT-3′ for miR-122-5P; and 5′-FCTCGCTTCGGCAGCCACA-3′ and 5′-AACGCTTCACGAATTTGCGT-3′ for U6.

Cell transfection
-----------------

Three shRNAs targeting LINC01296 were designed (Hanbio Biotechnology Co. Ltd., Shanghai, China), with sequences of 5′-GCCCTGCAGCAGCAGCGGCGTG GTCA-3′ (shRNA1), 5′-GAGCAGCGGCGTGGTCA GAGCGAGCT-3′ (shRNA2), and 5′-GCACACACACAC AAGCTGGCTCACAG-3′ (shRNA3). The shRNAs were inserted into the lentiviral vector HBLV-H-Scramble-GFP-PURO (Hanbio, Shanghai, China), that is, LINC01296 shRNA1/2/3; negative control was named control shRNA with a sequence of 5′-TTCTCCGAACGTGTCACGTAA-3′. Full-length cDNA of LINC01296 was inserted into the len-tiviral vector (ie, LINC01296), and the empty vector was used as the control. All the shRNAs were transfected into Huh7 cells, and LINC01296 and the corresponding control vector were transfected into SMMC-7721 cells using poly-brene (Hanbio, Shanghai, China). miR-122-5P mimics and negative control, and miR-122-5P inhibitor (anti-miR-122; 5′-CAAACACCAUUGUCACACUCCA-3′) and negative control (GeneCopeia, Guangzhou, China) were transfected into cells using Lipofectamine2000 (Thermo Fisher Scientific, Waltham, MA, USA). Puromycin was added into the medium to remove uninfected cells. Cells were incubated for 24 hours before the assays.

Cell viability
--------------

Cells were seeded into a 96-well plate (2,500 cells/well) and cell viability was determined using a CCK8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) at 0, 24, 48, 72, and 96 hours.

Colony formation assay
----------------------

In a six-well plate, 500 cells/well were seeded. After incubation for 14 days, the cells were washed twice with PBS, fixed with methanol, and stained with crystal violet. The number of colonies containing \>5 cells was counted under a microscope. This experiment was performed three times.

Cell migration and invasion
---------------------------

For analysis of cell migration, 4·10^4^ cells were seeded in a transwell chamber (8-∝m pore size; EMD Millipore, Billerica, MA, USA) with 200 ∝L serum-free DMEM. A volume of 500 ∝L of the medium containing 10% FBS was added to the lower chamber. For invasion assay, following the above process, the Matrigel (diluted 1:9; Corning Incorporated, Corning, NY, USA) was spread on the upper surface of the membrane. After incubating for 24 hours (cell migration) or 36 hours (cell invasion), the cells on the lower surface of the membrane were fixed in 4% paraformaldehyde for 30 minutes and stained with 0.5% crystal violet. Cells in five predetermined fields were counted under a microscope (Ci-L; Nikon Corporation, Tokyo, Japan; magnification ·200). This experiment was performed five times.

Luciferase reporter assay
-------------------------

LINC01296 containing the predicted miR-122-5P binding site was cloned into pGL3-LINC01296-Wt (wild-type) and pGL3-LINC01296-Mut (mutant reporter) vectors (Pro-mega Corporation, Fitchburg, WI, USA). HEK-293T cells were co-transfected with miR-122-5P mimics or negative control, and pGL3-LINC01296-WT or pGL3-LINC01296-Mut using Lipofectamine2000 (Thermo Fisher Scientific). The luciferase activity was measured after 36 hours using the Dual-Luciferase Reporter Assay System (Promega Corporation).

Western blot
------------

Proteins were extracted with the RIPA buffer (Beyotime Institute of Biotechnology, Haimen, China). About 20 ∝g of proteins was separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane (EMD Millipore). The membrane was blocked with 8% skimmed milk diluted with Tris-buffered saline with Tween-20 (Tris-HCl 24.23 g/L, NaCl 80.06 g/L \[pH 7.5\], and 0.1% Tween \[1 mL\]) at room temperature for 1 hour and then incubated with the primary antibody (1:1,000) overnight at 4°C. Horseradish peroxidase-conjugated secondary antibody (1:2,000) was added and incubated for 1 hour. The targeted proteins were visualized with the ECL kit (EMD Millipore). The primary antibodies were rabbit polyclonal antibodies: anti-E-cadherin, anti-N-cadherin (Wanlei Life Science, Shenyang, China, 1:2,000), anti-vimentin, and anti-GAPDH (Bioss, Beijing, China, 1:4,000). The secondary antibody was a goat anti-rabbit IgG antibody. The relative band density was determined using ImageJ software (NIH, Bethesda, ML, USA).

Statistical analysis
--------------------

Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). The results were expressed as mean ± SD. Student's *t*-test was used to compare two groups. Differences among groups were analyzed using analysis of variance followed by the least significant difference post hoc analysis. The associations between LINC01296 expression and clinical pathological factors were analyzed using chi-squared test. A value of *P*\<0.05 was set as the critical value.

Results
=======

LINC01296 was upregulated in HCC tissues
----------------------------------------

Microarray data indicated that there were four upregulated lncRNAs with higher abundance (average fragments per kilobase of transcript per million fragments mapped \[FPKM\] \[normal\] \>0.5, average FPKM \[tumor\] \>5) and differential expression (log2 fold change \[tumor/normal\] \>2) in primary HCC tissues ([Table 1](#t1-ott-12-2193){ref-type="table"}). GEPIA was performed to compare the expression of these four lncRNAs between HCC and paired normal liver tissues, and the data demonstrated that they were more highly expressed in HCC ([Figure 1A](#f1-ott-12-2193){ref-type="fig"}). To further verify the difference, RT-qPCR was performed by using tissues from five patients, and the results indicated that three lncRNAs (ZFPM2-AS1, LINC01296, and LINC00978) were upregulated in HCC tissues compared with the PT ([Figure 1B](#f1-ott-12-2193){ref-type="fig"}).

LINC01296 presented the highest difference and was therefore selected as the focus of the research. In the TCGA data set, a higher expression level of LINC01296 was confirmed in HCC tissues (n=374) compared with that in normal tissues (n=50) ([Figure 1C](#f1-ott-12-2193){ref-type="fig"}), and a survival analysis was performed using the median expression level of LINC01296 as the cutoff value (0.030756) in 370 HCC patients. Patients with higher LINC01296 levels in tumor tissues had a lower overall survival rate ([Figure 1D](#f1-ott-12-2193){ref-type="fig"}). These data manifested that LINC01296 was highly expressed in HCC and that a higher expression level predicted a poor prognosis.

Furthermore, HCC tissues and paired PT were collected from 50 patients, and the relationship between LINC01296 expression and clinicopathological variables was analyzed. Higher expression levels of LINC01296 were observed in HCC tissues compared with the PT ([Figure 1E](#f1-ott-12-2193){ref-type="fig"}), and the expression level of LINC01296 was positively correlated with TNM stage, tumor size, and the alpha fetoprotein (AFP) level ([Table 2](#t2-ott-12-2193){ref-type="table"}). These suggest that the expression level of LINC01296 may be a biomarker for HCC.

LINC01296 promoted cell proliferation, migration, and invasion
--------------------------------------------------------------

The mRNA levels of LINC01296 were increased in HCC cell lines (Hep-3B, SMMC-7721, HepG2, and Huh7) compared with that in a normal hepatocyte cell line (HL-7702), with the highest basal level observed in Huh7 cells and the lowest basal level observed in SMMC-7721 cells ([Figure 2A](#f2-ott-12-2193){ref-type="fig"}). Therefore, to investigate its biological functions, LINC01296 was overexpressed in SMMC-7721 cells ([Figure 2B](#f2-ott-12-2193){ref-type="fig"}) and conversely knocked down in Huh7 cells. ([Figure 2C](#f2-ott-12-2193){ref-type="fig"}). Cell proliferation was increased in SMMC-7721 cells after LINC01296 overexpression, while it was inhibited in Huh7 cell with LINC01296 knockdown ([Figure 2D--F](#f2-ott-12-2193){ref-type="fig"}). Moreover, LINC01296 overexpression promoted cell migration, while LINC01296 knockdown inhibited cell migration ([Figure 2G](#f2-ott-12-2193){ref-type="fig"}); similar effects were also observed in the invasion behavior ([Figure 2H](#f2-ott-12-2193){ref-type="fig"}).

LINC01296 promoted EMT
----------------------

E-cadherin, N-cadherin, and vimentin are EMT markers involved in cancer metastasis. It has been reported that LINC01296 could promote metastasis by affecting EMT in colon carcinoma and pancreatic ductal adenocarcinoma.[@b17-ott-12-2193],[@b30-ott-12-2193] In order to verify the role of LINC01296 on HCC metastasis, the expression of the EMT markers was measured using Western blot. LINC01296 overexpression decreased the E-cadherin level and increased the levels of N-cadherin and Vimentin in SMMC-7721 cells ([Figure 3A](#f3-ott-12-2193){ref-type="fig"}). LINC01296 knockdown resulted in an increase in E-cadherin and a decrease in N-cadherin and Vimentin in Huh7 cells ([Figure 3B](#f3-ott-12-2193){ref-type="fig"}).

LINC01296 interacted with miR-122-5P
------------------------------------

Bioinformatics analysis showed that miR-122-5P has the most binding sites closely targeting the 3′-UTR of LINC01296 ([Figure 4A](#f4-ott-12-2193){ref-type="fig"}). The binding within LINC01296-Wt and miR-122-5P was also confirmed in HEK-293T cells by luciferase reporter assay ([Figure 4B](#f4-ott-12-2193){ref-type="fig"}). In order to confirm that miR-122-5P could induce the decay of LINC01296, miR-122-5P was overexpressed in SMMC-7721 cells ([Figure 4C](#f4-ott-12-2193){ref-type="fig"}) and was knocked down in Huh7 cells ([Figure 4D](#f4-ott-12-2193){ref-type="fig"}). The expression levels of LINC01296 were reduced in SMMC-7721 cells after miR-122-5P overexpression ([Figure 4E](#f4-ott-12-2193){ref-type="fig"}) and were elevated in Huh7 cells after miR-122-5P knockdown ([Figure 4F](#f4-ott-12-2193){ref-type="fig"}).

Meanwhile, LINC01296 as a "sponge" of miR-122-5P could suppress the expression of miR-122-5P. Indeed, LINC01296 overexpression decreased the expression levels of miR-122-5P in SMMC-7721 cells ([Figure 4G](#f4-ott-12-2193){ref-type="fig"}), while its knockdown increased the levels of miR-122-5P in Huh7 cells ([Figure 4H](#f4-ott-12-2193){ref-type="fig"}). In 50 patients with HCC, miR-122-5P was found to be downregulated relative to that in the PT ([Figure 4I](#f4-ott-12-2193){ref-type="fig"}), and a negative correlation between LINC01296 and miR-122-5P was noted in the 50 HCC tissues ([Figure 4J](#f4-ott-12-2193){ref-type="fig"}). These demonstrated that LINC01296 and miR-122-5P could suppress each other's expression by mutual binding.

miR-122-5P reversed the function of LINC01296
---------------------------------------------

In order to further investigate the role of miR-122-5P in the biological response of HCC induced by LINC01296, SMMC-7721 cells were transfected with LINC01296 with/ without miR-122-5P mimics ([Figure 5A](#f5-ott-12-2193){ref-type="fig"}), and Huh7 cells were transfected with LINC01296-shRNA3 with/without a miR-122-5P inhibitor ([Figure 5B](#f5-ott-12-2193){ref-type="fig"}). There were no differences in the LINC01296 expression levels between miR-122-5P and control mimics in SMMC-7721 cells transfected with LINC01296, which may be ascribed to the overexpression of LINC01296 induced by lentivirus. Therefore, Huh7 cells transfected with LINC01296-shRNA3 with/without a miR-122-5P inhibitor were used for rescue experiments. The cellular proliferation, migration, and invasion induced by LINC01296 knockdown were reversed by a miR-122-5P inhibitor ([Figure 5C--F](#f5-ott-12-2193){ref-type="fig"}). Similar reversal effects were also observed in EMT ([Figure 5G](#f5-ott-12-2193){ref-type="fig"}). These indicated that the effect of LINC01296 on HCC could be attributed to the inhibition of miR-122-5P.

Discussion
==========

lncRNAs are a large subgroup of noncoding transcripts that have emerged as crucial regulators and prognostic markers in multiple cancers including HCC.[@b31-ott-12-2193] Currently, lncRNAs are considered as the key in the development of novel cancer treatments because targeting oncogenic lncRNAs is a way to more directly induce an anticancer effect,[@b32-ott-12-2193] such as EGFR and VEGFR as potential target for biological therapies in HCC cells.[@b8-ott-12-2193] In the present study, a novel lncRNA, LINC01296, was identified using microarray data to be a recurrently dysregulated lncRNA in human primary HCC. Its expression was increased in HCC cell lines and tissues, which is consistent with the results obtained through the GEPIA and TCGA databases. In addition, LINC01296 expression was increased in patients with larger tumor sizes (\>5 cm), higher AFP levels (\>400 ng/mL), higher TNM grades, and a poorer 10-year survival. These suggested that LINC01296 is a potential diagnostic and prognostic biomarker. Furthermore, LINC01296 was involved in oncogenesis and promoted cellular proliferation, migration, and invasion in HCC cells. In previous studies, LINC01296 was shown to be an oncogene in some cancers, including gastric cancer, colon carcinoma, cholangiocarcinoma, and prostate cancer,[@b16-ott-12-2193]--[@b19-ott-12-2193] indicating that LINC01296 is an extensively carcinogenic gene.

HCC is a serious malignant tumor characterized by metastasis.[@b33-ott-12-2193] Currently, evidence that shows a crucial role of EMT in tumor metastasis is accumulating.[@b34-ott-12-2193] Due to the lncRNA-miRNA-mRNA ceRNA network, lncRNAs open new opportunities in understanding the role of EMT in metastasis; moreover, lncRNAs are more known as ceRNAs in the regulation of EMT.[@b35-ott-12-2193] Further efforts toward elucidating the underlying function of lncRNAs are needed. In previous studies, LINC01296 was confirmed as the ceRNA of miR-21a in colon carcinoma[@b17-ott-12-2193] and miR-5095 in cholangiocarcinoma.[@b18-ott-12-2193] LINC01296 silencing inhibited the proliferation and invasion of cells due to EMT in colon carcinoma.[@b17-ott-12-2193] In the present study, LINC01296 promoted EMT and positively correlated with HCC metastasis. In addition, miR-122-5P was verified to be a binding target of LINC01296 and it could reverse the proliferation, migration, invasion, and EMT of HCC cells induced by LINC01296. Though it is known that miR-122-5P negatively regulates the EMT induced by LINC01296, the pathway downstream of LINC01296 that lead to EMT is still not clear.

lncRNAs can act as a sponge for miRNAs to reduce miRNA regulatory effects;[@b25-ott-12-2193],[@b26-ott-12-2193] the concentration of miRNAs can be titrated by the abundant lncRNAs that harbor similar microRNA target sequences and sequester miRNAs away from their target mRNAs.[@b23-ott-12-2193] Another interesting finding in the study is that LINC01296 could decrease the expression of miR-122-5P, demonstrating a negative correlation between LINC01296 and miR-122-5P in HCC tissues. These results suggest that LINC01296 could act as a sponge for miR-122-5P to regulate its biological effects. miR-122 is the most abundant miRNA in the adult liver, and it is a central player in liver biology and disease.[@b36-ott-12-2193] A previous study showed that miR-122 is a tumor inhibitor that is downregulated in HCC,[@b37-ott-12-2193] which is consistent with our results. Furthermore, miR-122 has been shown to be an essential host factor for hepatitis C virus infection and is an antiviral target that is complementary to the standard of care using direct-acting antivirals or interferon-based treatments.[@b36-ott-12-2193] Based on the above discussion, we can speculate that LINC01296, as a direct binding molecule of miR-122, could play a key role in the pathophysiology and treatment of HCC. Further study is needed to confirm the regulatory effect of LINC01296 on HCC. In addition, some signaling pathways of miR-122 in EMT have been demonstrated. For example, miR-122 can suppress EMT by targeting Snail1, Snail2,[@b38-ott-12-2193] and RhoA,[@b28-ott-12-2193] as well as suppress the WNT/®-cadherin signaling pathway.[@b38-ott-12-2193] A systematic study concerning the mechanism of EMT mediated by the interaction of LINC01296 and miR-122-5P is essential.

Conclusion
==========

In summary, here we report for the first time that LINC01296 could promote progression and metastasis of HCC cells by promoting EMT, while miR-122-5P could interact with LINC01296 and reverse its biological effects. Further research on LINC01296 is expected to provide new diagnostic and therapeutic targets for the treatment of HCC in the clinic.
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![LINC01296 is upregulated in HCC. (**A**) Expression levels of LINC00978, LINC01296, ZFPM2-AS1, and ELF3-AS1 in HCC and paired normal liver tissues were analyzed from GEPIA database. (**B**) Expression levels of four selected lncRNAs were qualified with RT-qPCR in five HCC and paired PTs (^\*\*^*P*\<0.01). (**C**) Expression levels of LINC01296 in 374 HCC tissues and 50 normal liver tissues were analyzed from TCGA database (^\*\*\*\*^*P*\<0.0001). (**D**) Overall survival was analyzed in 370 HCC tissues from TCGA database (*P*=0.0398). (**E**) Expression levels of LINC01296 were detected by performing RT-qPCR in 50 HCC and paired PTs (^\*\*\*^*P*\<0.001).\
**Abbreviations:** HCC, hepatocellular carcinoma; GEPIA, Gene Expression Profiling Interactive Analysis; RT-qPCR, reverse transcription quantitative PCR; TCGA, The Cancer Genome Atlas; PT, pericancerous tissue.](ott-12-2193Fig1){#f1-ott-12-2193}

![LINC01296 promotes proliferation, migration, and invasion of HCC cells. (**A**) Expression levels of LINC01296 in four HCC cell lines and HL-7702 cells. (**B**) Expression levels of LINC01296 in SMMC-7721 cells transfected with LINC01296. (**C**) Expression levels of LINC01296 in Huh7 cells transfected with three LINC01296 shRNAs. (**D** and **E**) CCK8 assays and (**F**) clone formation assays in SMMC-7721 cells with LINC01296 overexpression and Huh7 cells with LINC01296 knockdown. (**G**) Migration assays and (**H**) Invasion assays in SMMC-7721 cells with LINC01296 overexpression and Huh7 cell with LINC01296 knockdown. (^\*\*^*P*\<0.01 compared to blank/control group).\
**Abbreviations:** HCC, hepatocellular carcinoma; CCK8, cell counting kit 8.](ott-12-2193Fig2){#f2-ott-12-2193}

![LINC01296 promotes EMT. (**A**) Western blot analysis of EMT-related markers in SMMC-7721 cells transfected with LIN01296. (**B**) Western blot analysis of EMT-related markers in Huh7 cell transfected with LIN01296-shRNA3. ^\*\*^*P*\<0.01 compared to control group.\
**Abbreviation:** EMT, epithelial--mesenchymal transition.](ott-12-2193Fig3){#f3-ott-12-2193}

![LINC01296 interacts with miR-122-5P. (**A**) miR-122-5P and its predicted binding sites in the LINC01296 sequence. (**B**) Luciferase activities in HEK-293T cells co-transfected with miR-122-5P mimics/control mimics and LINC01296-Wt/LINC01296-Mut. (**C** and **D**) Expression levels of miR-122-5P in SMMC-7721 cells transfected with miR-122-5P mimics and Huh7 cells transfected with a miR-122-5P inhibitor. (**E** and **F**) Expression levels of LINC01296 in SMMC-7721 cells transfected with miR-122-5P mimics and Huh7 cells transfected with a miR-122-5P inhibitor. (**G** and **H**) Expression levels of miR-122-5P in SMMC-7721 cells transfected with LINC01296 and Huh7 cells transfected with LINC01296-shRNA3. (**I**) Expression levels of miR-122-5P in 50 HCC and paired PTs. (**J**) Correlation between LINC01296 and miR-122-5P in 50 HCC tissues. ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001 compared to control group.\
**Abbreviations:** HCC, hepatocellular carcinoma; PT, pericancerous tissue.](ott-12-2193Fig4){#f4-ott-12-2193}

![miR-122-5P reverses the biological function of LINC01296 in HCC cells. (**A**) Expression levels of LINC01296 in SMMC-7721 cells transfected with LINC01296 and/or miR-122-5P. (**B**) Expression levels of LINC01296 in Huh7 cells transfected with LINC01296-shRNA3 and/or miR-122-5p inhibitor. (**C**) CCK8 assays, (**D**) Clone formation assays, (**E**) Migration assays, and (**F**) Invasion assays in Huh7 cells transfected with LINC01296-shRNA3 and/or miR-122-5p inhibitor. (**G**) Western blot analysis of EMT-related markers in Huh7 cells transfected with LINC01296-shRNA3 and/or miR-122-5p inhibitor. ^\*\*^*P*\<0.01 compared to control group.\
**Abbreviations:** HCC, hepatocellular carcinoma; EMT, epithelial--mesenchymal transition; CCK8, cell counting kit 8.](ott-12-2193Fig5){#f5-ott-12-2193}

###### 

Four selected lncRNAs from microarray database

  Gene ID           Gene          Average FPKM (normal)   Average FPKM (tumor)   Average FPKM Log2 fold change (tumor/normal)   *P*-value
  ----------------- ------------- ----------------------- ---------------------- ---------------------------------------------- -------------
  ENSG00000251003   *ZFPM2-AS1*   0.60374475              8.51625825             3.818206357                                    0.000850677
  ENSG00000244306   *LINC01296*   0.7626481               9.6995527              3.66883394                                     1.91E--5
  ENSG00000234678   *ELF3-AS1*    0.98327255              5.493271               2.482001516                                    1.91E--6
  ENSG00000172965   *LINC00978*   6.9771975               35.876685              2.362326804                                    5.72E--6

**Abbreviation:** FPKM, fragments per kilobase of transcript per million fragments mapped.

###### 

Correlation of LINC01296 expression with clinico-pathologic variables

  Clinicopathologic parameter   No of patients                                           LINC01296 expression   Chi-squared *P*-value   
  ----------------------------- -------------------------------------------------------- ---------------------- ----------------------- --------
  **Age (years)**                                                                                                                       0.5287
  ≤60                           15                                                       5                      10                      
  \>60                          35                                                       15                     20                      
  **Gender**                    0.4814                                                                                                  
  Male                          37                                                       13                     24                      
  Female                        13                                                       6                      7                       
  **HBsAg**                     0.3295                                                                                                  
  Yes                           38                                                       13                     25                      
  No                            12                                                       6                      6                       
  **AFP (ng/mL)**               0.0105[\*](#tfn3-ott-12-2193){ref-type="table-fn"}                                                      
  ≤400                          17                                                       11                     6                       
  \>400                         33                                                       9                      24                      
  **Tumor size (cm)**           0.0375[\*](#tfn3-ott-12-2193){ref-type="table-fn"}                                                      
  ≤5                            30                                                       18                     12                      
  \>5                           20                                                       6                      14                      
  **Vascular invasion**         0.8634                                                                                                  
  Yes                           34                                                       14                     20                      
  No                            16                                                       7                      9                       
  **Tumor number**              0.3357                                                                                                  
  Single                        19                                                       10                     9                       
  Multiple                      31                                                       12                     19                      
  **TNM stage**                 0.0003[\*\*\*](#tfn4-ott-12-2193){ref-type="table-fn"}                                                  
  I--II                         16                                                       13                     3                       
  III--IV                       34                                                       9                      25                      

**Notes:** The median expression level was used as the cutoff. Low expressions of LINC01296 in 50 patients was classified as values below the 50th percentile. High expressions of LINC01296 in 50 patients was classified as values above the 50th percentile.

*P*\<0.05.

*P*\<0.001.

**Abbreviations:** HBsAg, Australia antigen; AFP, alpha fetoprotein.
